146293-11-0 Usage
General Description
The chemical compound ((1-(tert-Butoxycarbonyl)piperidin-4-yl)-methyl)triphenylphosphonium iodide is a quaternary ammonium salt with the formula C30H35IN2O2P. It is composed of a piperidine ring with a tert-butoxycarbonyl group, a methyl group, and a triphenylphosphonium group attached. ((1-(tert-Butoxycarbonyl)piperidin-4-yl)-methyl)triphenylphosphonium iodide is commonly used as a reactant in organic synthesis and serves as a stable, easily-handled source of a reactive piperidinium cation. It has applications in the synthesis of pharmaceuticals and other complex organic compounds. Additionally, the compound has potential uses in drug design and development due to its structural features and reactivity. Overall, ((1-(tert-Butoxycarbonyl)piperidin-4-yl)-methyl)triphenylphosphonium iodide is a versatile chemical that plays a significant role in organic chemistry and the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 146293-11-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,6,2,9 and 3 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 146293-11:
(8*1)+(7*4)+(6*6)+(5*2)+(4*9)+(3*3)+(2*1)+(1*1)=130
130 % 10 = 0
So 146293-11-0 is a valid CAS Registry Number.
146293-11-0Relevant articles and documents
AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS
-
Page/Page column 135, (2008/06/13)
Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+,K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.
